Novartis today announced that Cosentyx® (secukinumab) met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial 1. Cosentyx demonstrated statistically significant and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback